The Cooper Companies, Inc. $COO Stock: Robeco Institutional Asset Management B.V. Raises Position

Robeco Institutional Asset Management B.V. boosted its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 834.6% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 112,677 shares of the medical device company’s stock after buying an additional 100,621 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Cooper Companies were worth $6,370,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in Cooper Companies by 84.0% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 52,747 shares of the medical device company’s stock valued at $2,982,000 after acquiring an additional 24,084 shares in the last quarter. TD Waterhouse Canada Inc. acquired a new position in shares of Cooper Companies in the 3rd quarter valued at about $2,669,000. Trail Ridge Investment Advisors LLC lifted its position in shares of Cooper Companies by 17.1% in the third quarter. Trail Ridge Investment Advisors LLC now owns 12,293 shares of the medical device company’s stock worth $695,000 after purchasing an additional 1,793 shares in the last quarter. V Square Quantitative Management LLC lifted its position in shares of Cooper Companies by 18.8% in the third quarter. V Square Quantitative Management LLC now owns 8,698 shares of the medical device company’s stock worth $492,000 after purchasing an additional 1,377 shares in the last quarter. Finally, State of Alaska Department of Revenue lifted its position in shares of Cooper Companies by 71.5% in the third quarter. State of Alaska Department of Revenue now owns 41,044 shares of the medical device company’s stock worth $2,320,000 after purchasing an additional 17,118 shares in the last quarter. 24.39% of the stock is owned by hedge funds and other institutional investors.

Cooper Companies Stock Performance

Shares of COO stock opened at $61.21 on Friday. The Cooper Companies, Inc. has a fifty-two week low of $51.01 and a fifty-two week high of $89.83. The stock’s 50-day moving average is $61.79 and its two-hundred day moving average is $65.77. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.22 and a quick ratio of 0.73. The firm has a market cap of $11.64 billion, a P/E ratio of 20.89, a PEG ratio of 2.49 and a beta of 0.83.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.03. The business had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.10 billion. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%. The firm’s revenue was up .5% on a year-over-year basis. During the same period in the previous year, the company earned $0.49 EPS. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Analysts predict that The Cooper Companies, Inc. will post 4.53 earnings per share for the current fiscal year.

Cooper Companies announced that its board has initiated a stock repurchase plan on Wednesday, September 9th that allows the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization allows the medical device company to reacquire up to 22.7% of its stock through open market purchases. Share repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.

Insider Activity at Cooper Companies

In other Cooper Companies news, Director Walter M. Rosebrough, Jr. bought 7,000 shares of the firm’s stock in a transaction on Friday, September 11th. The stock was bought at an average cost of $54.11 per share, with a total value of $378,770.00. Following the completion of the transaction, the director directly owned 17,000 shares of the company’s stock, valued at approximately $919,870. The trade was a 70.00% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Paul A. Keel bought 4,701 shares of the firm’s stock in a transaction on Friday, September 11th. The stock was acquired at an average cost of $53.18 per share, with a total value of $249,999.18. Following the completion of the transaction, the director directly owned 4,701 shares of the company’s stock, valued at approximately $249,999.18. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have acquired 34,701 shares of company stock valued at $1,880,039. 2.08% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Piper Sandler restated a “neutral” rating on shares of Cooper Companies in a report on Thursday, October 15th. Wells Fargo & Company set a $61.00 price objective on shares of Cooper Companies and gave the company an “equal weight” rating in a research note on Thursday, September 10th. Robert W. Baird set a $61.00 target price on shares of Cooper Companies and gave the stock a “neutral” rating in a research report on Thursday, September 10th. Mizuho set a $75.00 target price on shares of Cooper Companies and gave the stock an “outperform” rating in a research report on Thursday, September 10th. Finally, Weiss Ratings raised shares of Cooper Companies from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, September 18th. Four investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $68.60.

About Cooper Companies

CooperCompanies is a global medical device company that develops, manufactures and markets products for vision care and women’s health. The company operates through two primary business segments: CooperVision and CooperSurgical.

CooperVision provides contact lenses and related technologies, including products designed for myopia management, astigmatism, presbyopia and other vision-correction needs. Its portfolio includes daily disposable, reusable and specialty contact lenses sold through eye-care professionals and distributors.

CooperSurgical develops products and services for fertility and women’s health.